Jian He

Mr. Jian He

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
JHJian He
Jian He
ZQZihao Qi
Zihao Qi
XZXiaofei Zhang
Xiaofei Zhang
YYYufei Yang
Yufei Yang
FLFei Liu
Fei Liu
ZWZiliang Wang
Ziliang Wang
Barasertib is a highly selective Aurora kinase B (AURKB) inhibitor and has been widely applied in a variety of cancer cells to investigate the regulatory function of AURKB. However, the effect of barasertib on glucose metabolism in gastric cancer (GC) remains illustrated. Here, barasertib was identified to effectively reduce glucose uptake and lactate production in GC cells in a dose-dependent and time-dependent manner. The expression levels of GLUT1, LDHA and HK2 were decreased by barasertib treatment of GC cells. Furthermore, we found that barasertib induced the expression of ribosomal protein S7 (RPS7), as a tumor suppressor, to regulate glucose metabolism. Silencing of RPS7 rescued the effects of barasertib on glucose metabolism in GC cells. Overexpression of RPS7 suppressed the promoter activity of C-Myc, which has been identified as an important regulator of glucose metabolism in cancer cells. The clinical data showed that the expression level of AURKB in GC patients’ sera and tissues were positively correlated with those of C-Myc, GLUT1 and LDHA, but negatively with that of RPS7. Therefore, these findings provide new evidence that barasertib regulates GC cell glucose metabolism by inducing the RPS7/C-Myc signal pathway, and have important implications for the development of therapeutic approaches using AURKB as a target protein to prevent tumor recurrence.

31 July 2014 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
Jia WuJia Wu
Jia Wu
WCWei Guo Chen
Wei Guo Chen
XCXiao Song Chen
Xiao Song Chen
OHOu Huang
Ou Huang
JHJian He
Jian He
KSKunwei Shen
Kunwei Shen
The aim of the present study was to investigate whether breast cancer patients with changes from positive to negative in the hormone receptor following neoadjuvant chemotherapy (NAC) could benefit from adjuvant endocrine therapy (ET). Between December 2000 and November 2010, 97 eligible patients with a positive-to-negative switch of the hormone receptor status following NAC were identified. All the patients were categorized into two groups on the basis of the administration of ET: 57 ET-administered and 40 ET-naïve patients. Survival analyses were performed to examine the prognostic value of ET administration, as well as other clinical and pathological variables. The administration of ET was associated with a significantly improved disease-free survival (DFS) (P=0.018) in patients with a positive-to-negative switch of the hormone receptor status. The 5-year DFS rates were 77.0 and 55.5% in ET-administered and ET-naïve patients, respectively. The 5-year overall survival (OS) rate for ET-administered was also higher than that of the ET-naïve patients (81.3 vs. 72.7%, P=0.053), but the difference between the two groups did not reach a statistical significance. The present study revealed that patients with the hormone receptor that was altered from positive to negative following NAC benefit from ET, and the hormone receptor status should be evaluated not only in specimens obtained during post-NAC surgery, but also in specimens biopsied prior to NAC.

12 January 2024 in Cancer Medicine
Verified
Journal Article
Open access
ASArnethea Sutton
Arnethea Sutton
JHJian He
Jian He
WBWendy Bottinor
Wendy Bottinor
SHSusan Hong
Susan Hong
KMKristyn Mitchell
Kristyn Mitchell
AHAnika L. Hines
Anika L. Hines
Purpose: Breast cancer survivors are at increased risk of cardiovascular dysfunction following their diagnosis; however, hypertension remains underexplored within this context. This retrospective cohort study examined the incidence of hypertension in breast cancer survivors and the association of race with hypertension risk among them.Methods: Data for this study were abstracted from the electronic health records of women diagnosed with Stages I–III breast cancer. Incident hypertension diagnosis was identified through International Classification of Diseases codes. Bivariate associations were tested using Student's t‐test and chi‐squared test of independence. Bivariable Cox regression analysis was used to determine demographic and clinical factors that may have been associated with the development of hypertension.Results: A total of 664 women were included. Most women were 50 years of age or younger (52.0%), White (33.0% Black), and received a mastectomy (80.6%). Overall, 45.5% of the cohort developed hypertension. The 1‐year hypertension‐free survival estimates were 47% (95% confidence interval [CI], 41–54) in Black women and 73% (95% CI, 69–77) in White women (p < 0.0001). Besides race, statistically significant predictors of hypertension included: age greater than 50 (vs. ≤50) (adjusted Hazard Ratio [HR]: 1.40; 95% CI, 1.09–1.80) and residing in a non‐metropolitan area (vs. metropolitan) (adjusted HR: 1.60; 95% CI, 1.19–2.16).Conclusions: This study suggests that breast cancer survivors who are older, Black, or residing in non‐metropolitan areas may benefit from added surveillance and hypertension prevention strategies during treatment. Future studies are needed to identify contributors to the observed racial and geographic disparities.

5 November 2026 in Cancer Medicine
Verified
Journal Article
Open access
ASArnethea Sutton
Arnethea Sutton
JHJian He
Jian He
RPRobert A. Perera
Robert A. Perera
LCLakeshia Cousin
Lakeshia Cousin
KPKeesha L. Powell-Roach
Keesha L. Powell-Roach
WBWendy Bottinor
Wendy Bottinor
Background: Breast cancer survivors are at increased risk of cardiovascular disease throughout survivorship. Recent studies documented suboptimal adherence to cardiovascular risk reduction medications, but studies identifying contributors to this behavior are lacking. The association between sociodemographic characteristics, social drivers of health factors, and cost‐related medication behaviors in survivors who were taking antihyperlipidemics or antihypertensives was evaluated. Methods: These cross‐sectional analyses utilized data from the National Institutes of Health All of Us Research Program from May 31, 2017 to October 1, 2023. Cohort eligibility included identifying as Black/African American or White, being at least 18 years old, and having a diagnosis of breast cancer. The outcome, cost‐related medication underuse and coping behaviors, was assessed using a seven‐item scale. Bivariable and multivariable logistic regression models were used to evaluate the associations of covariates and the outcome for each of the cardiovascular risk medication classes. Results: Compared to Black survivors, White survivors had higher odds of asking for lower‐cost medications among antihyperlipidemics users (pooled adjusted OR = 1.69; 95% CI: 1.18–2.40; FDR‐adjusted p = 0.012) and antihypertensives users (pooled adjusted OR = 2.03; 95% CI: 1.50–2.76; FDR‐adjusted p = 0.004). Survivors who reported greater social support were less likely to delay filling their prescription to save money when compared to survivors who reported lower social support. Conclusions: Some survivors are more likely to engage in cost‐related coping and underuse behaviors than others. Clinicians, including primary care providers, should include discussions and resources about non‐cancer therapy adherence‐related financial challenges with their patients who are cancer survivors.

2 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SWS. Jennifer Wang
S. Jennifer Wang
CHCarolyn Haynes
Carolyn Haynes
LGLaura Graham
Laura Graham
AKAkhila Kunuthuru
Akhila Kunuthuru
GTGina Tuzzolo
Gina Tuzzolo
Harry D. BearHarry D. Bear
Harry D. Bear
Background: Immune-checkpoint blockade (ICB) is a recent addition to the treatment options for breast cancer, especially the triple-negative (TNBC) subset. Inhibiting immunosuppressive factors in the tumor microenvironment (TME) and preventing or reversing T cell exhaustion may increase the likelihood of a response to ICB. We have shown that decitabine and guadecitabine, DNA methyltransferase inhibitors (DNMTi), prevent the systemic and TME accumulation of myeloid-derived suppressor cells (MDSCs), which are immunosuppressive. Results: Here, we show that adding DNMTi to the neoadjuvant + adjuvant ICB-based treatment of ICB-resistant 4T1 and E0771 murine tumors in Balb/C and C57Bl/6 mice, respectively, effectively reduced the tumor burden, with 52% of 4T1 tumors completely regressing across several studies. DNMTi-based therapy overcame ICB resistance (ICBR) in a selected subline of E0771, and treated tumors showed a reduction in MDSCs. We also show that, in E0771, DNMTi can overcome ICBR to multiple checkpoint inhibitors, and in 4T1, it can modulate anti-tumor immunity by enhancing central memory T cell (Tcm) formation and reducing T cell exhaustion. Conclusion: These pre-clinical findings support the further investigation of incorporating DNMTi as a new immunotherapy modality for TNBC.

19 June 2026 in Clinical Breast Cancer
Verified
Journal Article
Open access
JLJubin K. Lim
Jubin K. Lim
AGAnna E. Gibson
Anna E. Gibson
JHJian He
Jian He
AAAlexis Antonucci
Alexis Antonucci
Harry D. BearHarry D. Bear
Harry D. Bear
Hormone receptor-positive breast cancer (HR + BC) responds well to neoadjuvant endocrine therapy (NET), increasing chances for breast conserving surgery with less toxicity than neoadjuvant chemotherapy (NCT). A National Cancer Database study found that NET use increased by only 0.5% between 2004 and 2012. We investigated the utilization of NET, NCT, and no neoadjuvant therapy (no NT) from 2005 to 2023. We queried the TriNetX database for patients with HR + BC (stages I-III, ER+, PR+, ERBB2-) who underwent mastectomies in the US and evaluated utilization of NET, NCT, or no NT. We trended each use by all ages, age ≤ 50 years, or ≥ 51 years across roughly 5-year increments. NET cases were less than 10 for 2005-2009, and rounding obscured the exact count, so this period was excluded from the trend analysis. The use of NET remained below 1%, while NCT utilization was approximately 11%, and breast conserving surgery was achieved more frequently with NET than NCT (p < .0001). Both therapy types were used more frequently with advanced cancer stage (p < .0001), and NCT use was higher than NET in both age groups (p < .0001). NET and NCT use did not show significant trends when all ages were combined (p = .39). However, age-stratified analyses revealed significant declines in NCT use within each age group, with similar NET patterns and increasing no NT (p < .0001), indicating that overall results may mask weighted subgroup trends. This study highlights underutilization of NET, despite its low toxicity and efficacy in improving patient outcomes. Increased efforts are needed to address this gap and consider NET as an option for HR + BC.